Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mesoblast Limited (MESO) vs Rockwell Automation (ROK) Price & Performance

Mesoblast LimitedTrade
Rockwell AutomationTrade

Price performance (Past 24H)

Key statistics

Mesoblast Limited vs Rockwell Automation — how do they compare? Mesoblast Limited trades at $16.68 (market cap $2.16B), while Rockwell Automation trades at $447 (market cap $48.33B). The key difference: Rockwell Automation is far larger — about 22.4× Mesoblast Limited's market cap, and Rockwell Automation pays a 1.27% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.

MESOROK
Market Cap
$2.16B$48.33B
Sector
TechnologyIndustrials
52-Week High
$20.96$495.08
52-Week Low
$12.88$333.75
Enterprise Value
$2.17B$51.46B
Dividend Yield
1.27%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Rockwell Automation

Rockwell Automation (ROK) trades at $441.04, down 0.17% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 49.09% gross margin and 13.38% net income margin, but elevated valuation ratios like a P/E of 41.3 suggest premium pricing. Q3 2026 results exceeded expectations, driven by organic sales growth and margin expansion, prompting raised full-year guidance.

The outlook is mixed: analyst consensus leans bullish with a $480.25 price target (30% buy ratings), but technical weakness and high valuation pose near-term risks. Key catalysts include sustained automation demand and cost management, while inflation and competitive pressures remain headwinds for shareholder returns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO

About Rockwell Automation

Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.

Read more on ROK